30 Day Trial

NuVasive 3Q15 Revenue Up 7.8% CC vs. 3Q14


NuVasive posted 3Q15 revenue of US $200.5MM, +5.6% as reported and +7.8% in constant currency, and YTD 2015 revenue of $595.8MM, +6.7% as reported.

ORTHOWORLD estimates 3Q15 revenue by segment and as reported growth to be Spinal Implants, $156.3MM, +6.5%, Biologics $34.7MM, +6.4% and Monitoring $9.5MM, -9.9%.

While additional detail will be available following the quarterly earnings call, company leadership called out growth drivers such as strong sales in the U.S. and certain ex-U.S. geographies where NUVA leads with XLIF technology. 

Source: NuVasive, Inc.